| 000 | 01123 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250513032100.0 | ||
| 264 | 0 | _c19951122 | |
| 008 | 199511s 0 0 eng d | ||
| 022 | _a1078-0467 | ||
| 024 | 7 |
_a10.1007/978-1-4615-1823-5_5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFast, P E | |
| 245 | 0 | 0 |
_aClinical considerations in vaccine trials with special reference to candidate HIV vaccines. _h[electronic resource] |
| 260 |
_bPharmaceutical biotechnology _c1995 |
||
| 300 |
_a97-134 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAIDS Vaccines _xadverse effects |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aHIV Infections _ximmunology |
| 650 | 0 | 4 |
_aHIV-1 _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aOutcome Assessment, Health Care |
| 650 | 0 | 4 | _aResearch Design |
| 650 | 0 | 4 |
_aVaccines _xadverse effects |
| 700 | 1 | _aSawyer, L A | |
| 700 | 1 | _aWescott, S L | |
| 773 | 0 |
_tPharmaceutical biotechnology _gvol. 6 _gp. 97-134 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/978-1-4615-1823-5_5 _zAvailable from publisher's website |
| 999 |
_c7550711 _d7550711 |
||